Cancer-associated thrombosis: prevention and treatment

Current Oncology

Volumn 15, Issue S1, 2008, Pages S58-S67

  Brose, K M J ^a   Lee, A Y Y ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

deep vein thrombosis; heparin; low molecular weight heparin; Neoplasm; pro phylaxis; thromboembolism; warfarin

Indexed keywords

EID: 85127051490     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2008.177     Document Type: Article

References (58)

1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809–15.
2. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006;119:60–8.
3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632–4.
4. Sørensen HT, Mellemkjær L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–50.
5. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutro-penic cancer patients. J Clin Oncol 2006;24:484–90.
6. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international nor-malized ratio: a retrospective analysis. J Clin Oncol 2000;18: 3078–83.
7. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during antico-agulant treatment in patients with cancer and venous throm-bosis. Blood 2002;100:3484–8.
8. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in U.S. medical centers: success or failure? J Thromb Haemost 2007;5:1610–16.
9. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Anti-thrombotic and Thrombolytic Therapy. Chest 2004;126(suppl): 338S–400S.
10. Enoxacan Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099–103.
11. McLeod RS, Geerts WH, Sniderman KW, et al. Subcutane-ous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a ran-domized, double-blind trial. Ann Surg 2001;233:438–44.
12. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M on behalf of the PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005;92:1212–20.
13. Bergqvist D, Agnelli G, Cohen AT, et al. on behalf of the ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975–80.
14. Rasmussen MS, Wille–Jorgensen P, Jorgensen LN, et al. Pro-longed thromboprophylaxis with low molecular weight heparin (dalteparin) following major abdominal surgery for malignancy [abstract 186]. Blood 2003;102:56a.
15. Nurmohamed MT, van Riel AM, Henkens CM, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996;75:233–8.
16. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339:80–5.
17. Goldhaber SZ, Dunn K, Gerhard–Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002; 122:1933–7.
18. Macdonald RL, Amidei C, Baron J, et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol 2003;59:362–71.
19. Heilmann L, Kruck M, Schindler AE. Prevention of thrombosis in gynecology: double-blind comparison of low molecular weight heparin and unfractionated heparin [German]. Geburts-hilfe Frauenheilkd 1989;49:803–7.
20. Clark–Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein throm-bosis. Obstet Gynecol 1990;75:684–9.
21. Fricker JP, Vergnes Y, Schach R, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988;18:561–7.
22. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997;77: 456–61.
23. Heilmann L, von Tempelhoff GF, Kirkpatrick C, Schneider DM, Hommel G, Pollow K. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: effi-cacy, safety, and follow-up. Clin Appl Thromb Hemost 1998; 4:268–73.
24. Haas S, Wolf H, Kakkar AK, Fareed J, Encke A. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost 2005;94:814–19.
25. Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost 2005;94:867–71.
26. Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913–30.
27. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89–95.
28. Marras LC, Geerts WH, Perry JR. The risk of venous throm-boembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89:640–6.
29. Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemor-rhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998;43:1074–9.
30. Oates–Whitehead RM, D’Angelo A, Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. Cochrane Database Syst Rev 2003;:CD003679.
31. Wells PS, Lensing AW, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembo-lism. A meta-analysis. Arch Intern Med 1994;154:67–72.
32. Clarke–Pearson DL, Dodge RK, Synan I, McClelland RC, Maxwell GL. Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression. Obstet Gynecol 2003;101:157–63.
33. Clarke–Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168:1146–53.
34. Clarke–Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncol-ogy: report of a randomized controlled trial. Gynecol Oncol 1984;18:226–32.
35. Clarke–Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous throm-boembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984;63: 92–8.
36. Lyman GH, Khorana AA, Falanga A, et al. on behalf of the American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490–505.
37. Mandalà M, Falanga A, Piccioli A, et al. for working group AIOM. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006;59:194–204.
38. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboem-bolism in stage IV breast cancer. Lancet 1994;343:886–9.
39. Haas S, Kakkar A, Kemkes–Matthes B, et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer—results of the TOPIC studies. J Thromb Haemost 2005;3(suppl 1): OR059.
40. Perry JR, Rogers L, Laperriere N, et al. PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma [abstract]. Proc Am Soc Clin Oncol 2007;25:2011.
41. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319–23.
42. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98: 1614–15.
43. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–5.
44. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol 2002;20:1446–8.
45. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembo-lism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325–9.
46. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ on behalf of the PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-con-trolled trial of dalteparin for the prevention of venous throm-boembolism in acutely ill medical patients. Circulation 2004; 110:874–9.
47. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous throm-boembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793–800.
48. Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:1404–8.
49. Couban S, Goodyear M, Burnell M, et al. Randomized pla-cebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063–9.
50. Young AM, Begum G, Billingham LJ, et al. on behalf of the WARP Collaborative Group U.K. WARP—a multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs) [abstract]. Proc Am Soc Clin Oncol 2005;23: 8004.
51. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057–62.
52. Karthaus M, Kretzschmar A, Kröning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289–96.
53. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53.
54. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162: 1729–35.
55. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J on behalf of the ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin fol-lowed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389–96.
56. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecu-lar-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062–72.
57. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic dis-ease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):401S–28S.
58. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409–16.